In “the first in a series of conversations with officials at the Centers for Disease Control and Prevention (CDC) discussing the CDC’s role in global HIV and tuberculosis (TB) research and development,” the Center for Global Health Policy’s “Science Speaks” blog interviews Kayla Laserson, director of the Kenya Medical Research Institute (KEMRI)/CDC Field Research Station in Kisumu, Kenya. Laserson answers questions about her work with the CDC, the latest research projects underway at KEMRI/CDC, and progress in Kenya’s HIV response since she began working in Kisumu six years ago, among other topics (Mazzotta, 2/14).
“President Barack Obama [on Monday] proposed a $3.8 trillion budget for fiscal 2013 that aims to slash the deficit by $4 trillion over 10 years,” the Associated Press reports, and provides an agency-by-agency breakdown of the proposed budget (2/13). “Making up just one percent of the U.S. Government’s overall budget, the Department of State/USAID budget totals $51.6 billion,” a U.S. Department of State fact sheet notes (2/13). “Overall, funding for the Global Health Initiative (GHI) is down in the FY 2013 request, with most of the reduction coming from HIV/AIDS bilateral amounts,” according to the Kaiser Family Foundation’s Policy Tracker. “Most other areas saw decreases as well, except for family planning and funding for the Global Fund to Fight AIDS, Tuberculosis and Malaria and the GAVI Alliance, which increased,” the resource adds. The budget plan proposes a total of approximately $8.5 billion for GHI, down more than $300 million from FY 2012, the resource notes, adding that $6.4 billion of that funding would go to PEPFAR, including about $4.5 billion for HIV and $224 million for tuberculosis. The Global Fund receives $1.65 billion in the request, according to the resource (2/13).
In this post in USAID’s “IMPACTblog,” Ed Scholl, AIDSTAR-One project director, writes about HIV and tuberculosis (TB) care in Brazil, where “USAID has partnered with the Brazilian Ministry of Health to improve early TB detection, increase HIV counseling and testing, and provide medical treatment for both infections.” He continues, “AIDSTAR-One, a USAID-funded project, is also conducting outreach in Brazilian prisons, which are often at high risk of TB and HIV epidemics.” He concludes, “Through partnerships like USAID and AIDSTAR-One, we can effectively fight TB and HIV across Brazil and Latin America, to improve the health of countless people and ultimately save lives” (2/7).
USAID on Monday said it has “delivered the first two of 17 planned laboratory devices” to help quickly diagnose drug-resistant strains of tuberculosis (TB), VOA’s “Breaking News” blog reports. “It says the machines allow for technicians to diagnose multi-drug resistant tuberculosis within as little as two hours, instead of the previous time requirement of several months,” the blog writes. The “new lab devices, along with 12,000 testing cartridges, will be given to tuberculosis hospitals and clinics in more than 10 Vietnamese provinces,” according to the news service (2/6).
“[T]he highest levels ever of drug-resistant tuberculosis (TB) have been found in Russia and Moldova,” the WHO reports in research published in the February edition of the WHO Bulletin, but “the agency didn’t have data from most of Africa and India, where tuberculosis rates are much higher,” the Associated Press/USA Today’s “Your Life” reports. According to the AP, the “experts reported that about 29 percent of new TB patients in parts of Russia were drug-resistant” and that “65 percent of previously treated patients in Moldova had resistance problems.” The news service notes, “Normally, less than five percent of TB cases are drug-resistant” (2/2).
“Tuberculosis (TB) is the number one killer of the black population in South Africa, the S.A. Institute of Race Relations (SAIRR) said on Thursday,” South Africa’s Times Live reports. “Spokeswoman Lerato Moloi said the population group was also most affected by flu, pneumonia and intestinal infectious diseases such as cholera” and that “colored people died predominantly of TB, followed by diabetes and chronic lower respiratory diseases,” the news service writes.
The Guardian examines the future of the Global Fund to Fight AIDS, Tuberculosis and Malaria as it enters its second decade, writing, “Despite its staggering successes — including helping put 3.3 million people on AIDS treatment, 8.6 million on anti-tuberculosis treatment and providing 230 million insecticide-treated nets for the prevention of malaria — the fund’s recent troubles had threatened to overshadow its accomplishments as it prepared to mark a decade as the world’s main financier of programs to fight these three global epidemics.” The news service highlights a $750 million pledge to the Fund by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, discusses recent managerial changes within the Fund, and quotes a number of experts about future challenges (Kelly, 2/2).
In this New York Times opinion piece, Paul Farmer, chair of the department of global health and social medicine at Harvard Medical School and a co-founder of Partners in Health, examines the importance of the Global Fund to Fight AIDS, Tuberculosis and Malaria as it faces a “serious financial shortfall,” writing, “Beyond AIDS, the Global Fund is currently the largest donor in the world for tuberculosis and malaria programs. … The question is not whether the Global Fund works, but how to ensure it keeps working for years to come.”
“A pilot community program to improve [tuberculosis (TB)] detection in northern Tanzania has shown good results and could be replicated nationwide as the country seeks to improve its TB treatment and prevention systems,” IRIN reports. The program, run by Management Sciences for Health with help from PATH and Tanzania’s National Tuberculosis and Leprosy Programme and financial support from USAID, “emphasized that TB and HIV treatment must be done ‘hand in hand,'” according to IRIN.
In this post in the Center for Global Development’s (CGD) “Rethinking U.S. Foreign Assistance” blog, Connie Veillette, director of CGD’s rethinking U.S. foreign assistance initiative, highlights two recent posts by CGD’s Amanda Glassman and Nandini Oomman on the future of the Global Health Initiative (GHI). She writes, “With the Appropriations Committee weighing in by requiring a status report by mid-February on transitioning GHI to USAID, it is no understatement that the GHI is at an important juncture. Declining budgets for foreign assistance will also require new thinking on where the U.S. provides assistance and for what purpose” (1/31).